Objective: To examine the impact of onabotulinumtoxinA treatment in adult patients with spasticity on caregiver burden over 2 years from the Adult Spasticity International Registry (ASPIRE).

Background: ASPIRE is an international, multicenter, prospective, observational registry (NCT01930786) examining adults with spasticity who were treated with onabotulinumtoxinA per clinician discretion.

Method: Assessments included the 15-item Bakas Caregiver Outcomes Scale (BCOS; self-reported at enrollment and 5±1 weeks following patient treatment).

Results: 730 patients received ≥1 dose of onabotulinumtoxinA. Patients were, on average, 53.6 years old (range: 18.5–93.2 years); 52% were female, 77% white, and the majority had moderate to severe spasticity at baseline. 37% (n=269) were naive to botulinum toxins for treatment of spasticity. For the naive patient population, 122 associated caregivers completed the BCOS at baseline. Caregivers were, on average, 58.2 years old (range: 26.9–90.7 years); 61% were female, and 72% Caucasian. The majority of caregivers were the spouse or live-in partner of the patient (60%) or were another family member (33%). Approximately half of the caregivers were employed (39% full-time, 11% part-time) and approximately one-third (34%) were retired. In comparison with their BCOS scores at baseline, caregivers (n=24; post-treatment 2) reported statistically significant improvements (p<0.05) in the categories of time for family activities, level of energy, emotional well-being, time for social activities with friends, and general health following onabotulinumtoxinA treatment for the patient.

Conclusion: In ASPIRE, caregivers of patients treated with onabotulinumtoxinA for spasticity reported less burden. Reduced burden was associated with an increase in caregiver quality of life, as indicated by increased time for family and friends, more energy, and improvements in emotional and general health. ASPIRE provides valuable, real-world data on onabotulinumtoxinA utilisation and effectiveness in patients, as well as the impact of treatment on caregiver burden. These results demonstrate the value of onabotulinumtoxinA for the treatment of spasticity in clinical practice.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/onabotulinumtoxina-treatment-in-adults-with-spasticity-reduces-caregiver-burden-results-from-the-aspire-study/